Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET.

Biochemical pharmacology - 1 Aug 2021

Li Jing, Tan Guishan, Cai Yabo, Liu Ruihuan, Xiong Xiaolin, Gu Baohua, He Wei, Liu Bing, Ren Qingyun, Wu Jianping, Chi Bo, Zhang Hang, Zhao Yanzhong, Xu Yangrui, Zou Zhenxing, Kang Fenghua, Xu Kangping

Abstract excerpt

MET, the receptor of hepatocyte growth factor (HGF), is a driving factor in renal cell carcinoma (RCC) and also a proven drug target for cancer treatment. To improve the activity and to investigate the mechanisms of action of Apigenin (APG), novel derivatives of APG with improved properties were synthesized and their activities against Caki-1 human renal cancer cell line were evaluated. It was found that compound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Kidney Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Molecular Docking Simulation

Share to Molecular Structure

Share to Neoplasms, Experimental

Share to Phytotherapy

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 34043966
DOI: 10.1016/j.bcp.2021.114620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET.PMID 34043966Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsSemantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Semantic proximity Read ↗

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.Semantic proximity Read ↗

Hepatocyte growth factor activator inhibitor type-1 in cancer: Advances and perspectives (Review)Semantic proximity Read ↗

Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.Semantic proximity Read ↗

ELA/APELA precursor cleaved by furin displays tumor suppressor function in renal cell carcinoma through mTORC1 activationSemantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4Semantic proximity Read ↗

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.Semantic proximity Read ↗

Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.Semantic proximity Read ↗

Targeting c‐MET by LY2801653 for treatment of cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.